1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Nicox SA.
  6. News
  7. All News
    COX   FR0013018124

NICOX SA.

(COX)
  Report
Real-time Euronext Paris  -  11:35 2022-07-04 am EDT
1.718 EUR   -0.12%
06/22Nicox Extraordinary General Meeting of July 11, 2022
GL
06/22Nicox Extraordinary General Meeting of July 11, 2022
AQ
06/15NICOX : Suggested agenda and summary of the resolutions submitted to the approval of the Extraordinary shareholder meeting (translation for information purposes)
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
All news about NICOX SA.
06/22Nicox Extraordinary General Meeting of July 11, 2022
GL
06/22Nicox Extraordinary General Meeting of July 11, 2022
AQ
06/15NICOX : Suggested agenda and summary of the resolutions submitted to the approval of the E..
PU
06/15NICOX : How to participate in the Extraordinary shareholder meeting
PU
06/14NICOX : 2022 Ordinary Shareholder Meeting
GL
06/14NICOX : 2022 Ordinary Shareholder Meeting
GL
06/03NICOX : 2022 Extraordinary Shareholder Meeting
GL
06/03NICOX : 2022 Extraordinary Shareholder Meeting
AQ
06/03Ophthalmology Group Nicox To Release Data From Late-stage Glaucoma Drug Trial In Novemb..
MT
06/03Nicox Accelerates Topline Results from NCX 470 Mont Blanc Phase 3 Glaucoma Trial to Nov..
GL
06/03Nicox Accelerates Topline Results from NCX 470 Mont Blanc Phase 3 Glaucoma Trial to Nov..
AQ
06/03Nicox S.A. Accelerates Topline Results from NCX 470 Mont Blanc Phase 3 Glaucoma Trial t..
CI
05/16Ophthalmology Group Nicox Appoints New CEO, Chairman
MT
05/16Nicox Announces a New Governance Structure
GL
05/16Nicox Announces a New Governance Structure
AQ
05/16Nicox S.A. Announces Executive Changes
CI
05/04NICOX : 2022 Ordinary Shareholder Meeting
GL
05/04NICOX : 2022 Ordinary Shareholder Meeting
AQ
05/02NICOX AT ARVO 2022 : Presentation of clinical Phase 2 results on NCX 4251 and new non-clin..
GL
05/02NICOX AT ARVO 2022 : Presentation of clinical Phase 2 results on NCX 4251 and new non-clin..
AQ
04/28Nicox Reports 2021 Financial Results and First Quarter 2022 Financial Highlights and Pr..
AQ
04/11Nicox's NCX 470 Dolomites Phase 2 Results Published in Journal of Glaucoma
AQ
04/11Nicox’s NCX 470 Dolomites Phase 2 Results Published in Journal of Glaucoma
CI
03/03Nicox's Partner Fera Pharmaceuticals Obtains Orphan Drug Designation from the U.S. FDA ..
AQ
03/03Ocumension Therapeutics Says Phase III Study of Eye Drops in China Yields Positive Resu..
MT
03/02Nicox Partner Fera Pharmaceuticals Wins US FDA's Orphan Drug Designation for Sickle Cel..
MT
03/02Nicox's Partner Fera Pharmaceuticals Obtains Orphan Drug Designation from the U.S. FDA ..
AQ
03/01Nicox's Partner Ocumension Obtains Positive Phase 3 Clinical Trial Results for ZERVIATE..
GL
03/01Nicox’s Partner Ocumension Obtains Positive Phase 3 Clinical Trial Results for ZER..
CI
03/01Nicox's Partner Ocumension Obtains Positive Phase 3 Clinical Trial Results for ZERVIATE..
GL
02/23Nicox Announces VYZULTA Now Commercialized in 7 Territories and Approved in Further 9 C..
AQ
02/23Nicox Announces VYZULTA Now Commercialized in 7 Territories and Approved in Further 9 C..
CI
02/22France's Nicox Wins Japanese Patent for Dry Eye Disease Drug
MT
02/22Nicox Granted New Patent for NCX 4251 in Japan
AQ
02/21Nicox Receives New Chinese Patent For Ocular Hypertension Product
MT
02/21Nicox Granted New Patent for NCX 470 in China, Extending Coverage to 2039
AQ
02/21Nicox S.A. Announces Chinese National Intellectual Property Administration Grant A Form..
CI
02/08Nicox to Launch New Dry Eye Disease Study in 2023
MT
02/08Nicox's Positive FDA Meeting Shows Clear Path for NCX 4251 in Dry Eye
AQ
02/08Nicox’s Positive FDA Meeting Shows Clear Path for NCX 4251 in Dry Eye
CI
01/27Nicox to Participate in Financial, Pharmaceutical Industry and Scientific Events in H1 ..
AQ
01/21Nicox Provides Fourth Quarter 2021 Business and Financial Highlights
AQ
01/06NICOX : Half-year liquidity contract statement for NICOX
AQ
01/05Nicox Secures European Patent For Allergic Conjunctivitis Treatment
MT
01/05Nicox European Patent Seals ZERVIATE Major Market Coverage to 2030
AQ
2021Nicox Screens First Patient in China in Late-Stage Trial For Glaucoma Treatment
MT
2021Nicox Announces First Patient in China screened in the ongoing NCX 470 Denali Phase 3 T..
AQ
2021Nicox Announces First Patient in China screened in the ongoing NCX 470 Denali Phase 3 T..
CI
2021GLOBAL MARKETS LIVE : General Motors, JP Morgan, Pfizer, Novavax, Ford...
2021Nicox Appoints Novartis Executive as Chief Scientific Officer
MT
2021Nicox Appoints Doug Hubatsch as new Chief Scientific Officer to lead Clinical and Non-c..
AQ
2021Nicox Appoints Doug Hubatsch as New Chief Scientific Officer to Lead Clinical and Non-C..
CI
2021Nicox Raises $17 Million in Share Placement, Restructures Kreos Bond Financing Deal
MT
2021Nicox Restructures Kreos Capital Bond Financing Agreement and Raises €15 Million in Pri..
AQ
2021Number of voting rrights as of November 30, 2021
AQ
2021Nicox Reports Positive Results For Dry Eye Treatment Trial
MT
2021Nicox's Positive Post Hoc Results from NCX 4251 Phase 2b Mississippi Trial Suggest Path..
AQ
2021Nicox S.A. Announces Positive Post Hoc Results from Its Mississippi Phase 2B Clinical T..
CI
2021Nicox is Granted Patent for Blepharitis Product Candidate NCX 4251 in Europe
AQ
2021Nicox's NCX 470 Dolomites Phase 2 Results in Glaucoma Patients to be Presented at the A..
AQ
2021Nicox?s NCX 470 Dolomites Phase 2 Results in Glaucoma Patients to be Presented at the A..
CI
2021Number of voting rightts as of October 31
AQ
2021NICOX : Provides Third Quarter 2021 Business and Financial Highlights
AQ
2021NICOX : to present at the OIS Glaucoma Virtual Innovation Showcase
AQ
2021NICOX : Launches New Corporate & Investor Website
AQ
2021NICOX : Eye Drug Shows Retinal Cell Protection In Nonclinical Trial
MT
2021NICOX : NCX 470 Shows Retinal Cell Protection in a Nonclinical Model
AQ
2021Nicox SA Reports New Data on NCX 470 in Nonclinical Model of Retinal Cell Damage Induce..
CI
2021GLOBAL MARKETS LIVE : Intel, Apple, Rolls-Royce, Raytheon, MGM...
2021NICOX : First Half 2021 Financial Results and Business Update
AQ
2021Nicox S.A. Reports Earnings Results for the Half Year Ended June 30, 2021
CI
2021Nicox S.A. Announces Retirement of José Boyer as Interim Head of R&D
CI
2021GLOBAL MARKETS LIVE : Valneva,Boeing, Facebook, Kubota, Otis...
2021NICOX : Eye Drug Trial Fails To Meet Efficacy Endpoints
MT
2021NICOX : Announces Results from the NCX 4251 Phase 2b Mississippi Blepharitis Trial
AQ
1  2  3  4  5  6  7  8Next